NIH Public Access Author Manuscript Neuropharmacology. Author manuscript; available in PMC 2014 August 26. Published in final edited form as: Neuropharmacology. 2011 June; 60(0): 1007–1016. doi:10.1016/j.neuropharm.2010.10.021.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript
Epigenetic GABAergic Targets in Schizophrenia and Bipolar Disorder A. Guidotti*, J. Auta, Y. Chen, J.M. Davis, E. Dong, D.P. Gavin, D.R. Grayson, F. Matrisciano, G. Pinna, R. Satta, R.P. Sharma, L. Tremolizzo, and P. Tueting University of Illinois at Chicago, College of Medicine, Department of Psychiatry, Psychiatric Institute, 1601 Taylor, Chicago IL 60612
Abstract It is becoming increasingly clear that a dysfunction of the GABAergic/glutamatergic network in telencephalic brain structures may be the pathogenetic mechanism underlying psychotic symptoms in schizophrenia (SZ) and bipolar (BP) disorder patients. Data obtained in Costa’s laboratory (1996–2009) suggest that this dysfunction may be mediated primarily by a downregulation in the expression of GABAergic genes (e.g., glutamic acid decarboxylase67[GAD67] and reelin) associated with DNA-methyltransferase (DNMT)-dependent hypermethylation of their promoters. A pharmacological strategy to reduce the hypermethylation of GABAergic promoters is to administer drugs, such as the histone deacetylase (HDAC) inhibitor valproate (VPA), that induce DNA-demethylation when administered at doses that facilitate chromatin remodeling. The benefits elicited by combining VPA with antipsychotics in the treatment of BP disorder suggest that an investigation of the epigenetic interaction of these drugs is warranted. Our studies in mice suggest that when associated with VPA, clinically relevant doses of clozapine elicit a synergistic potentiation of VPA-induced GABAergic promoter demethylation. Olanzapine and quetiapine (two clozapine congeners) also facilitate chromatin remodeling but at doses higher than used clinically, whereas haloperidol and risperidone are inactive. Hence, the synergistic potentiation of VPA’s action on chromatin remodeling by clozapine appears to be a unique property of the dibenzepines and is independent of their action on catecholamine or serotonin receptors. By activating DNA-demethylation, the association of clozapine or its derivatives with VPA or other more potent and selective HDAC inhibitors may be considered a promising treatment strategy for normalizing GABAergic promoter hypermethylation and the GABAergic gene expression downregulation detected in the postmortem brain of SZ and BP disorder patients.
© 2010 Elsevier Ltd. All rights reserved. *
Corresponding author aguidotti@psych.uic.edu Tel. 312/413-4594, Fax 312/413-4594. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting,
and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

DNA methylation and demethylation神经疾病靶点_生物学_自然科学_专业资料。Pharmacological...Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuroph...
et al.Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet. 2011; 20: 4786-4796. Rogd...
et al.Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet. 2011; 20: 4786-4796. Rogd...
热门文档